|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.
|
22358385 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The most common mutation K-Ras(G12V), required for tumor proliferation, survival, and metastasis due to its constitutively active GTPase activity, has provided an ideal target for cancer therapy.
|
19014906 |
2009 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Meanwhile, based on the level of stromal infiltrating lymphocytes (SIL) infiltration, analysis of CRC patients was statistically associated with a location (p = 0.002), TNM stage (p < 0.001), metastasis (p < 0.001), and KRAS mutation (p = 0.031).
|
30370522 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In the lung cancer model, KRAS siRNA treatment demonstrated significant reductions in primary tumor growth and distant metastatic disease, while the addition of CDDP was not additive.
|
25281617 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, 1 limitation of this test is the heterogeneity of KRAS status, which can be either intratumoral heterogeneity within an individual primary CRC or discordant KRAS status between a primary CRC and its corresponding metastases.
|
26135109 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS-mutant NSCLC patients with concurrent LKB1 loss had a higher number of metastatic sites at the time of diagnosis (median 2.5 vs. 2, P = 0.01), higher incidence of extrathoracic metastases (P = 0.01), and developed brain metastasis more frequently (48% vs. 25%, P = 0.02).
|
25737507 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Here, we used a mouse model of KRAS-driven pancreatic carcinogenesis to define distinct subtypes of PDAC metastasis: epithelial, mesenchymal and quasi-mesenchymal.
|
26158412 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
TOPK expression is an unfavourable prognostic indicator in sporadic patients with KRAS or BRAF mutations and also in patients with metastatic disease experiencing a response to anti-EGFR therapies.
|
19935791 |
2010 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Mutated LN metastases displayed KRAS associated or not with BRAF mutations.
|
16953233 |
2007 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Surprisingly, let7a, a KRAS-targeting miR, showed elevated expression in metastatic disease compared to normal mucosa or non-metastatic disease, and only in KRAS mutation positive tumors.
|
22120473 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Patients with primary tumors possessing KRAS mutations had a shorter disease-free survival period after metastasis resection (12.0 vs 18.0 months; P = 0.035) than those who did not.
|
20020061 |
2009 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS oncogene testing is recommended in all patients with metastatic colorectal cancer due to its impact on treatment selection, but we do not know if KRAS genotype affects extent or pattern of metastases.
|
24906690 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Furthermore, through digital PCR analysis, we revealed potential genomic mechanisms for the KRAS and TP53 mutations in the metastatic tumor.
|
22797009 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Understanding oncogenic KRAS cellular reprogramming has the potential to reveal novel strategies to control metastasis in KRAS-driven cancers.
|
31681587 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
In particular, mutations in Kirsten rat sarcoma viral oncogene homolog gene (KRAS), alone or in combination with tumor protein p53 gene (TP53) mutations, were associated with decreased survival probability and with the occurrence of local metastases at recurrence.
|
27156442 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
This is the first report showing that identification of CRC patients at high risk for metastasis is possible by assessing MACC1 expression in combination with KRAS G13 mutation.
|
25742883 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Other clinicopathological features, such as age, location of the tumor, tumor differentiation, Tumor, Node and Metastases classification, and the Union for International Cancer Control staging, showed no positive relationship with K-ras gene mutations.
|
21390154 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
These results indicate that EGFR and KRAS mutations are present frequently in metastases and occur before metastasis.
|
25445553 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Mutational frequencies were significantly higher in patients with lung metastases compared with those with liver and ovary/bladder metastases (p = 0.039), however, KRAS mutation status was not associated with an increased risk of relapsed in the lung.
|
26887348 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Several recent studies have shown that patients with KRAS mutations in codons 12 or 13 in metastatic tumors do not benefit from anti-epidermal growth factor receptor therapy with cetuximab or panitumumab.
|
19792050 |
2009 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The significant associations of mutations were KRAS with age less than 60 years (p = 0.041), PIK3CA with males (p = 0.032), tumor stage I-II (p = 0.013), lack of metastasis in lymph nodes (p = 0.040), NRAS with rectum (p = 0.002), and APC with T2 stage of tumor growth (p = 0.013).
|
28222664 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262).
|
30826992 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
A bone marrow aspirate sampled at the site of progressing metastasis in the right iliac bone was performed, and single cell molecular analysis using array-CGH of Epithelial Specific Antigen (ESA)-positive metastatic cells, and revealed two distinct regions of amplification, 12p12.1 and 17q12-q21.2 amplicons, containing the KRAS (12p) and ERBB2 (HER2/NEU) (17q) oncogenes.
|
22014070 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This study enrolled 457 patients with surgically resected primary and corresponding metastatic CRC (499 synchronous metastases and 57 metachronous metastases) and seven local recurrences, and KRAS/BRAF mutation and MSI status were analysed for these tumours.
|
28000889 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
CRC in KSA is usually diagnosed at advanced stages with metastases and KRAS/BRAF, and is associated with poor prognosis and short survival.
|
27915339 |
2017 |